Stay updated on Nivolumab in Salivary Gland Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Salivary Gland Carcinoma Clinical Trial page.

Latest updates to the Nivolumab in Salivary Gland Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record for the NISCAHN phase II trial of nivolumab in recurrent or metastatic salivary gland carcinoma is displayed, with details about the study design, participants, locations, and measured outcomes.SummaryDifference52%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0, while the study record remains inaccessible with a 403 Forbidden message.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide NIH notice says federal agencies are transitioning to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI), and that both terms may appear during the transition.SummaryDifference1%

- Check29 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1 on the error page.SummaryDifference0.2%

- Check57 days agoChange DetectedAccess to the study record now shows a 403 Forbidden error page with the site header and footer. This blocks display of the study details and navigation that would normally appear on the record page.SummaryDifference18%

Stay in the know with updates to Nivolumab in Salivary Gland Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Salivary Gland Carcinoma Clinical Trial page.